Tinzaparin
Adenocarcinoma of the Colon
Ottawa Hospital Research Instituteother_biologicalPhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
47 Active assets in the Adenocarcinoma of the Colon cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eloxatin Sun Yat-sen University | Phase 3 | BBB |
FLUOROURACILUM Merck Sharp & Dohme LLC | Phase 3 | BBB |
Irinotecan Sun Yat-sen University | Phase 3 | BBB |
Irinotecan SWOG Cancer Research Network | Phase 3 | BBB |
Eloxatin Merck Sharp & Dohme LLC | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Tinzaparin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →